Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillaume Seret

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Nephrologie & Therapeutique|February 8, 2023
Maxence Ficheux, Guillaume Seret
Nephrology (Carlton, Vic.)|October 3, 2019
Rheopheresis: A new therapeutic approach in severe calciphylaxisThomas Robert, Arnaud Lionet, Stanislas Bataille, et al.
Clinical & Developmental Immunology|December 14, 2011
Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritisGuillaume Seret, Yannick Le Meur, Yves Renaudineau, et al.
Clinical Kidney Journal|November 8, 2016
Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritisGuillaume Seret, Catherine Hanrotel, Boutahar Bendaoud, et al.
Nephrologie & Therapeutique|October 24, 2019
[e-Health in nephrology: 1<sup>st</sup> French survey on telenephrology]Salvatore Citarda, Anne-Laure Camarroque, Guillaume Seret, et al.
Journal of Nephrology|December 15, 2024
Impact of iron and erythropoiesis-stimulating agent dose on mortality of hemodialysis patients with cancerArthur Michon-Colin, Yannis Lombardi, Guillaume Seret, et al.
Clinical Kidney Journal|November 22, 2021
Unmet needs for CKD care: from the general population to the CKD clinics-how many patients are we missing?Massimo Torreggiani, Antoine Chatrenet, Antioco Fois, et al.
Trials|May 26, 2021
VITADIAL "Does correction of 25 OH-VITAmin D with cholecalciferol supplementation increase muscle strength in hemoDIALysis patients?": study protocol for a randomized controlled trialStanislas Bataille, Nathalie Pedinielli, Elisa Carreno, et al.
Kidney International Reports|May 16, 2022
Incremental and Personalized Hemodialysis Start: A New Standard of CareMassimo Torreggiani, Antioco Fois, Antoine Chatrenet, et al.
Journal of Autoimmunity|June 14, 2015
Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritisGuillaume Seret, Felipe Cañas, Laurence Pougnet-Di Costanzo, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Nephrologie & Therapeutique|February 8, 2023
Maxence Ficheux, Guillaume Seret
Nephrology (Carlton, Vic.)|October 3, 2019
Rheopheresis: A new therapeutic approach in severe calciphylaxisThomas Robert, Arnaud Lionet, Stanislas Bataille, et al.
Clinical & Developmental Immunology|December 14, 2011
Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritisGuillaume Seret, Yannick Le Meur, Yves Renaudineau, et al.
Clinical Kidney Journal|November 8, 2016
Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritisGuillaume Seret, Catherine Hanrotel, Boutahar Bendaoud, et al.
Nephrologie & Therapeutique|October 24, 2019
[e-Health in nephrology: 1<sup>st</sup> French survey on telenephrology]Salvatore Citarda, Anne-Laure Camarroque, Guillaume Seret, et al.
Journal of Nephrology|December 15, 2024
Impact of iron and erythropoiesis-stimulating agent dose on mortality of hemodialysis patients with cancerArthur Michon-Colin, Yannis Lombardi, Guillaume Seret, et al.
Clinical Kidney Journal|November 22, 2021
Unmet needs for CKD care: from the general population to the CKD clinics-how many patients are we missing?Massimo Torreggiani, Antoine Chatrenet, Antioco Fois, et al.
Trials|May 26, 2021
VITADIAL "Does correction of 25 OH-VITAmin D with cholecalciferol supplementation increase muscle strength in hemoDIALysis patients?": study protocol for a randomized controlled trialStanislas Bataille, Nathalie Pedinielli, Elisa Carreno, et al.
Kidney International Reports|May 16, 2022
Incremental and Personalized Hemodialysis Start: A New Standard of CareMassimo Torreggiani, Antioco Fois, Antoine Chatrenet, et al.
Journal of Autoimmunity|June 14, 2015
Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritisGuillaume Seret, Felipe Cañas, Laurence Pougnet-Di Costanzo, et al.
Pageof 2